Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

139.17 -1.13 (-0.81%)
Streaming Delayed Price Updated: 2:24 PM EDT, Apr 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
72 73 Next >
News headline image
Friday's session: top gainers and losers in the S&P500 index ↗
Curious about the S&P500 stocks that are in motion on Friday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
News headline image
Is Gilead Sciences Gaining or Losing Market Support? ↗
 
Via Benzinga
News headline image
GILEAD SCIENCES INC (NASDAQ:GILD) Exhibits Quality Stock Traits. Here's Why. ↗
A fundamental analysis of (NASDAQ:GILD): Why GILEAD SCIENCES INC (NASDAQ:GILD) should be investigated by quality investors. 
Via Chartmill
News headline image
Gilead Presents New HIV Treatment And Cure Research Data ↗
Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety in early HIV treatment. 
Via Benzinga
News headline image
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
From Gilead Sciences, Inc.
Via Business Wire
News headline image
The Analyst Verdict: Gilead Sciences In The Eyes Of 14 Experts ↗
 
Via Benzinga
News headline image
First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet
From Gilead Sciences, Inc.
Via Business Wire
News headline image
These 3 Dividend Stocks Jumped 15% in a Month—More to Come?
Via MarketBeat
News headline image
Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
Gilead Sciences's Options: A Look at What the Big Money is Thinking ↗
 
Via Benzinga
News headline image
P/E Ratio Insights for Gilead Sciences ↗
 
Via Benzinga
News headline image
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years ↗
 
Via Benzinga
News headline image
Gilead Sciences Unusual Options Activity ↗
 
Via Benzinga
News headline image
Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with Myriad... 
Via StockStory
Topics Artificial Intelligence
News headline image
The Top Nasdaq-100 Stock in 2025 Has Nothing to Do With Artificial Intelligence (AI) ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
1 Value Stock with Exciting Potential and 2 to Ignore
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few... 
Via StockStory
News headline image
Best And Worst Performing S&P 500 Stocks Since Trump's Election Win ↗
Financial markets volatile since Trump's 2024 election, some companies surged like Palantir while others struggled such as First Solar. 
Via Benzinga
Topics Government Stocks
News headline image
How Is The Market Feeling About Gilead Sciences? ↗
 
Via Benzinga
News headline image
16 Analysts Have This To Say About Gilead Sciences ↗
 
Via Benzinga
News headline image
Salesforce Earnings Top Views. Software Stock Falls On Weak Revenue Outlook. ↗
Salesforce stock fell after the company's revenue guidance for fiscal 2026 came in below expectations, despite the ramp of new AI products. 
Via Investor's Business Daily
Topics Artificial Intelligence
News headline image
European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention
From Gilead Sciences, Inc.
Via Business Wire
News headline image
What To Expect From Myriad Genetics’s (MYGN) Q4 Earnings
Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting results tomorrow after market hours. Here’s what you need to know. 
Via StockStory
News headline image
Gilead Sciences: 4 Reasons This Stock Has Much More To Rise
Gilead Pharmaceuticals is back to highs not seen in a decade as its HIV treatment franchise surges and awaits its 100% effective HIV prevention drug in summer 
Via MarketBeat
Topics Death
News headline image
Eli Lilly Remains JPMorgan's Top Biopharma Pick For 2025, But Gilead And Bristol Myers Also Gain Praise — Is Retail On Board? ↗
JPMorgan sees Gilead well-positioned due to its strong HIV drug portfolio and disciplined expense management. 
Via Stocktwits
News headline image
Large Cap Biopharmaceutical Metrics And Performance Q1 2025 ↗
Tariffs could have big impact on earnings in 2025. 
Via Talk Markets
Topics Stocks / Equities
News headline image
Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
U.S. FDA Accepts Gilead’s New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review
From Gilead Sciences, Inc.
Via Business Wire
News headline image
This Bath & Body Works Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗
 
Via Benzinga
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
72 73 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.